Abstract
Background: Migraine is a highly disabling neurovascular primary headache disorder, with its exact pathomechanism being still unrevealed. The current leading hypotheses are based on the sensitization and activation of the trigeminovascular system.
Objective: To review the literature with focus on the effects of kynurenines (L-kynurenine and kynurenic acid) and pituitary adenylate cyclase-activating polypeptide on the regulation of the trigeminovascular system. Method: A literature search was conducted to identify preclinical and clinical publications (198 references) by using the keywords ‘kynurenines’, ‘pituitary adenylate cyclase-activating polypeptide’, and ‘migraine’ in the database of MEDLINE/PubMed up to 10 September 2016 for topical review. Additional filters used included ‘review’, ‘systematic review’, ‘original article’, and ‘English language’. Results: L-kynurenine and kynurenic acid act on the glutamatergic system at the level of the second-order nociceptive neurons in the trigeminal nucleus caudalis. Pituitary adenylate cyclase- activating polypeptide is released from the peripheral nerve endings of the trigeminal pseudounipolar neurons and causes vasodilation and mast cell degranulation, leading to consequent peripheral sensitization of the dural nociceptors. Centrally released pituitary adenylate cyclase-activating polypeptide in the trigeminal nucleus caudalis results in the central sensitization of the second-order neurons. The sensitization process leads to the characteristic features of migraine. Conclusion: L-kynurenine, kynurenic acid, and pituitary adenylate cyclase-activating polypeptide may have fundamental roles in the initiation of migraine headache attacks.Keywords: Glutamate, kynurenine, migraine, mode of action, pathomechanism, pituitary adenylate cyclaseactivating polypeptide.
Current Medicinal Chemistry
Title:Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects
Volume: 24 Issue: 13
Author(s): Janos Tajti, Delia Szok, Gabor Nagy-Grocz, Bernadett Tuka, Anna Petrovics-Balog, Jozsef Toldi and Laszlo Vecsei*
Affiliation:
- Department of Neurology, Faculty of Medicine, Albert Szent-Györgyi Clinical Center, University of Szeged, Semmelweis u. 6., H-6725, Szeged,Hungary
Keywords: Glutamate, kynurenine, migraine, mode of action, pathomechanism, pituitary adenylate cyclaseactivating polypeptide.
Abstract: Background: Migraine is a highly disabling neurovascular primary headache disorder, with its exact pathomechanism being still unrevealed. The current leading hypotheses are based on the sensitization and activation of the trigeminovascular system.
Objective: To review the literature with focus on the effects of kynurenines (L-kynurenine and kynurenic acid) and pituitary adenylate cyclase-activating polypeptide on the regulation of the trigeminovascular system. Method: A literature search was conducted to identify preclinical and clinical publications (198 references) by using the keywords ‘kynurenines’, ‘pituitary adenylate cyclase-activating polypeptide’, and ‘migraine’ in the database of MEDLINE/PubMed up to 10 September 2016 for topical review. Additional filters used included ‘review’, ‘systematic review’, ‘original article’, and ‘English language’. Results: L-kynurenine and kynurenic acid act on the glutamatergic system at the level of the second-order nociceptive neurons in the trigeminal nucleus caudalis. Pituitary adenylate cyclase- activating polypeptide is released from the peripheral nerve endings of the trigeminal pseudounipolar neurons and causes vasodilation and mast cell degranulation, leading to consequent peripheral sensitization of the dural nociceptors. Centrally released pituitary adenylate cyclase-activating polypeptide in the trigeminal nucleus caudalis results in the central sensitization of the second-order neurons. The sensitization process leads to the characteristic features of migraine. Conclusion: L-kynurenine, kynurenic acid, and pituitary adenylate cyclase-activating polypeptide may have fundamental roles in the initiation of migraine headache attacks.Export Options
About this article
Cite this article as:
Tajti Janos, Szok Delia, Nagy-Grocz Gabor, Tuka Bernadett, Petrovics-Balog Anna, Toldi Jozsef and Vecsei Laszlo*, Kynurenines and PACAP in Migraine: Medicinal Chemistry and Pathogenetic Aspects, Current Medicinal Chemistry 2017; 24 (13) . https://dx.doi.org/10.2174/0929867324666170227115019
DOI https://dx.doi.org/10.2174/0929867324666170227115019 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the Treatment of Chronic Inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Antiplatelet Therapy and Oral Anticoagulation for Prevention of Ischemic Stroke
Current Drug Therapy Potential Therapeutic Interest of Adenosine A2A Receptors in Psychiatric Disorders
Current Pharmaceutical Design Biomass-inspired Semiconductor Photocatalysts for Solar Degradation of Organics
Current Organic Chemistry New and Emerging Antiresorptive Treatments in Osteoporosis
Current Drug Safety Resistance to Imatinib in Chronic Myeloid Leukemia and Therapeutic Approaches to Circumvent the Problem
Cardiovascular & Hematological Disorders-Drug Targets Headache: One of the Most Common and Troublesome Adverse Reactions to Drugs
Current Drug Safety Phase 1 Single Dose Studies to Optimize the Pharmacokinetics of DG17, a Novel HIV-Protease Inhibitor Pro-Drug, Using Sodium Bicarbonate and Ritonavir
Current HIV Research Chinese Herbs as Immunomodulators and Potential Disease-Modifying Antirheumatic Drugs in Autoimmune Disorders
Current Drug Metabolism Molecular and Genetic Characteristics of Hereditary Autoinflammatory Diseases
Current Drug Targets - Inflammation & Allergy The Detection of Adverse Events in Randomized Clinical Trials: Can we Really Say New Medicines are Safe?
Current Drug Safety Potential Phytotherapeutic Approaches for the Treatment of Alzheimer’s Disease: An Overview
Current Traditional Medicine Management of Acute Aluminum Phosphide Poisoning: Has Anything Changed?
Drug Metabolism Letters Anti-Inflammation and Antimicrobial Constituents from the Roots and Their Production in Callus Cultures of Valeriana jatamansi Jones
Current Bioactive Compounds Sleep and Antidepressant Treatment
Current Pharmaceutical Design Serotonin Reuptake Inhibition: An Update on Current Research Strategies
Current Medicinal Chemistry New Antibiotics for Severe ICU-Aquired Bacterial Infections
Infectious Disorders - Drug Targets PDE5 Inhibitors in Non-Urological Conditions
Current Pharmaceutical Design Current and Future Therapies Targeting the Immune System in Multiple Sclerosis
Current Pharmaceutical Biotechnology Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Vitamin D as a Modulator of Neuroinflammation: Implications for Brain Health
Current Pharmaceutical Design